董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James B. McElwee | 男 | Director | 71 | 14.00万美元 | 未持股 | 2023-09-30 |
| Tamara N. Elias | 女 | Director | 51 | 13.75万美元 | 未持股 | 2023-09-30 |
| Jeffrey M. Soinski | 男 | President, Chief Executive Officer and Director | 61 | 60.52万美元 | 未持股 | 2023-09-30 |
| James G. Cullen | 男 | Director and Chairman of the Board | 80 | 16.75万美元 | 未持股 | 2023-09-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Himanshu N. Patel | 男 | Chief Technology Officer | 63 | 42.31万美元 | 未持股 | 2023-09-30 |
| Nabeel Subainati | 男 | Vice President, Finance, Principal Financial Officer and Principal Accounting Officer | 40 | 29.58万美元 | 未持股 | 2023-09-30 |
| Jeffrey M. Soinski | 男 | President, Chief Executive Officer and Director | 61 | 60.52万美元 | 未持股 | 2023-09-30 |
董事简历
中英对照 | 中文 | 英文- James B. McElwee
-
James B. McElwee 自 2011 年 3 月起担任 Avinger, Inc. 董事会成员。McElwee 先生自 2010 年起担任独立风险资本投资者。McElwee 先生曾担任 Weston Presidio 的普通合伙人， Weston Presidio 是一家私募股权和 风险投资公司，从 1992 年到 2010 年。在担任普通合伙人和投资委员会成员期间，Weston Presidio 领导了 JetBlue Airways 的启动融资，并投资了 Fender Musical Instruments、The Coffee Connection、吉他中心、Mapquest、 派对城、Petzazz、RE/MAX 等。
James B. McElwee,has served as a member of Avinger, Inc. board of directors since March 2011. Mr. McElwee has served as an independent venture capital investor since 2010. Mr. McElwee served as general partner of Weston Presidio, a private equity and venture capital firm, from 1992 to 2010. During his tenure as a general partner and member of the investment committee, Weston Presidio led the start up financing of JetBlue Airways and made investments in Fender Musical Instruments, The Coffee Connection, Guitar Center, Mapquest, Party City, Petzazz, RE/MAX, and others. - James B. McElwee 自 2011 年 3 月起担任 Avinger, Inc. 董事会成员。McElwee 先生自 2010 年起担任独立风险资本投资者。McElwee 先生曾担任 Weston Presidio 的普通合伙人， Weston Presidio 是一家私募股权和 风险投资公司，从 1992 年到 2010 年。在担任普通合伙人和投资委员会成员期间，Weston Presidio 领导了 JetBlue Airways 的启动融资，并投资了 Fender Musical Instruments、The Coffee Connection、吉他中心、Mapquest、 派对城、Petzazz、RE/MAX 等。
- James B. McElwee,has served as a member of Avinger, Inc. board of directors since March 2011. Mr. McElwee has served as an independent venture capital investor since 2010. Mr. McElwee served as general partner of Weston Presidio, a private equity and venture capital firm, from 1992 to 2010. During his tenure as a general partner and member of the investment committee, Weston Presidio led the start up financing of JetBlue Airways and made investments in Fender Musical Instruments, The Coffee Connection, Guitar Center, Mapquest, Party City, Petzazz, RE/MAX, and others.
- Tamara N. Elias
-
TamaraN.Elias于2019年12月被任命为我们的董事会成员。Elias博士目前担任默克公司（Merck）的副总裁兼全球合作伙伴关系主管。此前，她曾于2018年2月至2019年12月担任Aetna临床产品开发Vice President。从2015年到2017年，Elias博士是Becton Dickinson80亿美元医疗部门企业战略和业务发展的Vice President。从2007年到2015年，Elias博士是Essex Woodlands梦百合Partners的合伙人，该公司成立于1985年，是一家仅梦百合的成长型股权公司。在她职业生涯的早期，Elias博士是麦肯锡公司（McKinsey）的管理顾问，为制药、诊断和设备公司提供研发、产品商业化和并购方面的建议。她目前任职于Reva Medical公司的董事会，此前也曾任职于几家私人公司的董事会，包括出售给Pharmerica公司、BreatheAmerica公司和Influence Health公司（出售给HealthGrades公司）的千年药房系统公司，以及ATS Medical公司（出售给Medtronic公司）的上市公司董事会。Elias博士拥有耶鲁大学（Yale University）的生物学和人类学学位，以及约翰霍普金斯医学院（Johns Hopkins School of Medicine）的医学博士学位。她在马萨诸塞州总医院（Massachusetts General Hospital）接受普通外科医生培训。
Tamara N. Elias,was appointed to Avinger, Inc. board of directors in December 2019. Dr. Elias currently serves as SVP, Strategy and Business Incubation at Nuance Communications, a Microsoft Company. Previously she served as VP, Head of Global Partnerships at Merck from 2020 to 2022. Dr. Elias was VP, Clinical Product Development at Aetna from 2018 to 2020. From 2015 to 2017, Dr. Elias was Vice President of Corporate Strategy and Business Development for the $8 billion medical segment at Becton Dickinson. From 2007 to 2015, Dr. Elias was a Partner with Essex Woodlands Healthcare Partners, a healthcare only growth equity firm founded in 1985. Earlier in her career, Dr. Elias was a management consultant at McKinsey, advising pharmaceutical, diagnostic and device companies in R&D, product commercialization and M&A. She currently serves on the board of REVA Medical and BehaVR. Dr. Elias has previously served on the boards of several private companies, including Millennium Pharmacy Systems (sold to PharMerica), BreatheAmerica and Influence Health (sold to Healthgrades) as well as on the public company board of ATS Medical (sold to Medtronic). Dr. Elias holds degrees in Biology and Anthropology from Yale University, and an M.D. from The Johns Hopkins School of Medicine. She trained as a general surgeon at Massachusetts General Hospital. - TamaraN.Elias于2019年12月被任命为我们的董事会成员。Elias博士目前担任默克公司（Merck）的副总裁兼全球合作伙伴关系主管。此前，她曾于2018年2月至2019年12月担任Aetna临床产品开发Vice President。从2015年到2017年，Elias博士是Becton Dickinson80亿美元医疗部门企业战略和业务发展的Vice President。从2007年到2015年，Elias博士是Essex Woodlands梦百合Partners的合伙人，该公司成立于1985年，是一家仅梦百合的成长型股权公司。在她职业生涯的早期，Elias博士是麦肯锡公司（McKinsey）的管理顾问，为制药、诊断和设备公司提供研发、产品商业化和并购方面的建议。她目前任职于Reva Medical公司的董事会，此前也曾任职于几家私人公司的董事会，包括出售给Pharmerica公司、BreatheAmerica公司和Influence Health公司（出售给HealthGrades公司）的千年药房系统公司，以及ATS Medical公司（出售给Medtronic公司）的上市公司董事会。Elias博士拥有耶鲁大学（Yale University）的生物学和人类学学位，以及约翰霍普金斯医学院（Johns Hopkins School of Medicine）的医学博士学位。她在马萨诸塞州总医院（Massachusetts General Hospital）接受普通外科医生培训。
- Tamara N. Elias,was appointed to Avinger, Inc. board of directors in December 2019. Dr. Elias currently serves as SVP, Strategy and Business Incubation at Nuance Communications, a Microsoft Company. Previously she served as VP, Head of Global Partnerships at Merck from 2020 to 2022. Dr. Elias was VP, Clinical Product Development at Aetna from 2018 to 2020. From 2015 to 2017, Dr. Elias was Vice President of Corporate Strategy and Business Development for the $8 billion medical segment at Becton Dickinson. From 2007 to 2015, Dr. Elias was a Partner with Essex Woodlands Healthcare Partners, a healthcare only growth equity firm founded in 1985. Earlier in her career, Dr. Elias was a management consultant at McKinsey, advising pharmaceutical, diagnostic and device companies in R&D, product commercialization and M&A. She currently serves on the board of REVA Medical and BehaVR. Dr. Elias has previously served on the boards of several private companies, including Millennium Pharmacy Systems (sold to PharMerica), BreatheAmerica and Influence Health (sold to Healthgrades) as well as on the public company board of ATS Medical (sold to Medtronic). Dr. Elias holds degrees in Biology and Anthropology from Yale University, and an M.D. from The Johns Hopkins School of Medicine. She trained as a general surgeon at Massachusetts General Hospital.
- Jeffrey M. Soinski
-
JeffreyM.Soinski自2014年12月以来一直担任我们的总裁，首席执行官和董事会成员。从2009年9月Unisyn成立到2013年5月GE梦百合收购Unisyn业务，索因斯基一直担任Medical Imaging Holdings及其主要运营公司Unisyn Medical Technologies的首席执行官，为医学影像行业提供技术支持的产品和服务的国家提供商。Soinski先生自2009年9月起担任Medical Imaging Holdings及其剩余运营公司Consensys Imaging Service的董事，直至2017年10月出售。Soinski先生于2008年7月至2013年6月定期担任特殊风险合伙人，并自2016年10月起担任Galen Partners的特殊投资合伙人，Galen Partners是一家专注于梦百合的领先私募股权公司，其中包括医疗影像控股公司作为其投资组合公司之一。Soinski从2001年到2008年被C.R.Bard收购，担任Specialized Health Products International（专有安全医疗产品上市制造商和营销商）总裁和首席执行官。他曾任职Merriman Holdings公司（Merriman Capital公司（位于旧金山的投资银行和经纪公司）的母公司）的董事会（从2008年到2016年3月）。Soinski先生持有Dartmouth College的学士学位。
Jeffrey M. Soinski,has served as Avinger, Inc. President, Chief Executive Officer and a member of Avinger, Inc. Board of Directors since December 2014. From its formation in September 2009 until the acquisition of its Unisyn business by GE Healthcare in May 2013, Mr. Soinski served as Chief Executive Officer of Medical Imaging Holdings and its primary operating company Unisyn Medical Technologies, a national provider of technology-enabled products and services to the medical imaging industry. Mr. Soinski was a Director of Medical Imaging Holdings and its remaining operating company Consensys Imaging Service from September 2009 until its sale in October 2017. Mr. Soinski served periodically as a Special Venture Partner from July 2008 to June 2013 and as a Special Investment Partner since October 2016 for Galen Partners, a leading healthcare-focused private equity firm, which included Medical Imaging Holdings as one of its portfolio companies. From 2001 until its acquisition by C.R. Bard in 2008, Mr. Soinski was President and CEO of Specialized Health Products International, a publicly-traded manufacturer and marketer of proprietary safety medical products. He served on the board of directors of Merriman Holdings, parent of Merriman Capital, a San Francisco-based investment banking and brokerage firm, from 2008 until March 2016. Mr. Soinski holds a B.A. degree from Dartmouth College. - JeffreyM.Soinski自2014年12月以来一直担任我们的总裁，首席执行官和董事会成员。从2009年9月Unisyn成立到2013年5月GE梦百合收购Unisyn业务，索因斯基一直担任Medical Imaging Holdings及其主要运营公司Unisyn Medical Technologies的首席执行官，为医学影像行业提供技术支持的产品和服务的国家提供商。Soinski先生自2009年9月起担任Medical Imaging Holdings及其剩余运营公司Consensys Imaging Service的董事，直至2017年10月出售。Soinski先生于2008年7月至2013年6月定期担任特殊风险合伙人，并自2016年10月起担任Galen Partners的特殊投资合伙人，Galen Partners是一家专注于梦百合的领先私募股权公司，其中包括医疗影像控股公司作为其投资组合公司之一。Soinski从2001年到2008年被C.R.Bard收购，担任Specialized Health Products International（专有安全医疗产品上市制造商和营销商）总裁和首席执行官。他曾任职Merriman Holdings公司（Merriman Capital公司（位于旧金山的投资银行和经纪公司）的母公司）的董事会（从2008年到2016年3月）。Soinski先生持有Dartmouth College的学士学位。
- Jeffrey M. Soinski,has served as Avinger, Inc. President, Chief Executive Officer and a member of Avinger, Inc. Board of Directors since December 2014. From its formation in September 2009 until the acquisition of its Unisyn business by GE Healthcare in May 2013, Mr. Soinski served as Chief Executive Officer of Medical Imaging Holdings and its primary operating company Unisyn Medical Technologies, a national provider of technology-enabled products and services to the medical imaging industry. Mr. Soinski was a Director of Medical Imaging Holdings and its remaining operating company Consensys Imaging Service from September 2009 until its sale in October 2017. Mr. Soinski served periodically as a Special Venture Partner from July 2008 to June 2013 and as a Special Investment Partner since October 2016 for Galen Partners, a leading healthcare-focused private equity firm, which included Medical Imaging Holdings as one of its portfolio companies. From 2001 until its acquisition by C.R. Bard in 2008, Mr. Soinski was President and CEO of Specialized Health Products International, a publicly-traded manufacturer and marketer of proprietary safety medical products. He served on the board of directors of Merriman Holdings, parent of Merriman Capital, a San Francisco-based investment banking and brokerage firm, from 2008 until March 2016. Mr. Soinski holds a B.A. degree from Dartmouth College.
- James G. Cullen
-
James G. Cullen，自2005年以来，他担任NeuStar公司的总监。2010年以来，他担任董事会主席。2000年，他从一家当地电话交流运营商--大西洋贝尔公司以总裁兼董事会主席的身份辞职。1998年，在1995年担任副主席之后，他确认了那些职位。在那之前，自1993年以来，他担任总裁，1995年至1997年，他曾担任贝尔大西洋 - 新泽西公司的总裁兼首席执行官。他还担任总监、审计委员会成员、保德信金融集团的薪酬委员会主席、安捷伦科技公司的非执行董事长、Johnson & Johnson公司审计委员会的董事兼主席。
James G. Cullen,has served as a member of Avinger, Inc. board of directors since December 2014, as Avinger, Inc. Lead Independent Director since January 2015 and as Avinger, Inc. Non-Executive Chairman since December 2017. During the last five years, Mr. Cullen has held board and committee positions with various companies. Mr. Cullen is currently a director of Keysight Technologies, which was spun out of Agilent Technologies, where he was previously a director. Mr. Cullen previously served as a director and chairman of the audit committee of Johnson & Johnson and as a director and member of the investment and finance committees of Prudential Financial. From 1993 to 2000, Mr. Cullen was President, Vice Chairman and Chief Operating Officer of Bell Atlantic Corporation (now Verizon). From 1989 to 1993, he was President and Chief Executive Officer of Bell Atlantic-New Jersey. Mr. Cullen holds a B.A. in Economics from Rutgers University and an M.S. in Management Science from the Massachusetts Institute of Technology. - James G. Cullen，自2005年以来，他担任NeuStar公司的总监。2010年以来，他担任董事会主席。2000年，他从一家当地电话交流运营商--大西洋贝尔公司以总裁兼董事会主席的身份辞职。1998年，在1995年担任副主席之后，他确认了那些职位。在那之前，自1993年以来，他担任总裁，1995年至1997年，他曾担任贝尔大西洋 - 新泽西公司的总裁兼首席执行官。他还担任总监、审计委员会成员、保德信金融集团的薪酬委员会主席、安捷伦科技公司的非执行董事长、Johnson & Johnson公司审计委员会的董事兼主席。
- James G. Cullen,has served as a member of Avinger, Inc. board of directors since December 2014, as Avinger, Inc. Lead Independent Director since January 2015 and as Avinger, Inc. Non-Executive Chairman since December 2017. During the last five years, Mr. Cullen has held board and committee positions with various companies. Mr. Cullen is currently a director of Keysight Technologies, which was spun out of Agilent Technologies, where he was previously a director. Mr. Cullen previously served as a director and chairman of the audit committee of Johnson & Johnson and as a director and member of the investment and finance committees of Prudential Financial. From 1993 to 2000, Mr. Cullen was President, Vice Chairman and Chief Operating Officer of Bell Atlantic Corporation (now Verizon). From 1989 to 1993, he was President and Chief Executive Officer of Bell Atlantic-New Jersey. Mr. Cullen holds a B.A. in Economics from Rutgers University and an M.S. in Management Science from the Massachusetts Institute of Technology.
高管简历
中英对照 | 中文 | 英文- Himanshu N. Patel
Himanshu N. Patel 于 2007 年共同创立了 Avinger，并于 2011 年 1 月至 2011 年 11 月以及自 2013 年 10 月起担任 Avinger, Inc. 首席技术官。从 1999 年 9 月至 2007 年 2 月，Patel 先生担任过多个研发职位，包括 FoxHollow Technologies 高级技术总监。 Patel 先生此前曾在强生公司旗下的 EndoTex Interventional Systems、General Surgical Innovations 和 Ethicon 担任研发职位。 Patel先生在印度的巴罗达大学（University of Baroda）获得机械工程理学学士学位。在佛罗里达大学（University of Florida）获得机械工程理学硕士学位。
Himanshu N. Patel,co-founded Avinger in 2007 and has served as Avinger, Inc. Chief Technology Officer from January 2011 to November 2011 and then since October 2013. From September 1999 to February 2007, Mr. Patel held various research and development positions, including Director of Advanced Technologies, at FoxHollow Technologies. Mr. Patel previously held research and development positions at EndoTex Interventional Systems, General Surgical Innovations and Ethicon, a Johnson and Johnson company. Mr. Patel holds a B.S. in Mechanical Engineering from M.S. University of Baroda, India, and an M.S. in Mechanical Engineering from the University of Florida.- Himanshu N. Patel 于 2007 年共同创立了 Avinger，并于 2011 年 1 月至 2011 年 11 月以及自 2013 年 10 月起担任 Avinger, Inc. 首席技术官。从 1999 年 9 月至 2007 年 2 月，Patel 先生担任过多个研发职位，包括 FoxHollow Technologies 高级技术总监。 Patel 先生此前曾在强生公司旗下的 EndoTex Interventional Systems、General Surgical Innovations 和 Ethicon 担任研发职位。 Patel先生在印度的巴罗达大学（University of Baroda）获得机械工程理学学士学位。在佛罗里达大学（University of Florida）获得机械工程理学硕士学位。
- Himanshu N. Patel,co-founded Avinger in 2007 and has served as Avinger, Inc. Chief Technology Officer from January 2011 to November 2011 and then since October 2013. From September 1999 to February 2007, Mr. Patel held various research and development positions, including Director of Advanced Technologies, at FoxHollow Technologies. Mr. Patel previously held research and development positions at EndoTex Interventional Systems, General Surgical Innovations and Ethicon, a Johnson and Johnson company. Mr. Patel holds a B.S. in Mechanical Engineering from M.S. University of Baroda, India, and an M.S. in Mechanical Engineering from the University of Florida.
- Nabeel Subainati
Nabeel Subainati自2020年1月起担任公司副总裁兼公司财务总监。他被任命为Avinger, Inc.首席财务官和首席会计官，自2022年7月21日起生效。在加入本公司之前，Subainati先生于2018年7月至2020年1月担任半导体存储器技术提供商Crossbar，Inc.的财务总监。Subainati先生曾于2014年5月至2018年6月被Silicon Labs，Inc.收购之前担任西格玛设计公司的公司财务总监，该公司是一家在纳斯达克上市的家庭和工业应用集成片上系统解决方案提供商。在他职业生涯的早期，Subainati先生曾在Ernest & Young和Deloitte工作。他获得了学士学位在圣克拉拉大学获得工商管理学士学位，主修会计。他获得并目前持有有效的注册会计师称号。
Nabeel Subainati,has served in multiple capacities since January 2020. Currently Mr. Subainati is serving as the Company's Vice President, Finance, formerly Mr. Subainati held the position of Vice President, Corporate Controller. He was appointed to serve as Avinger, Inc. Principal Financial Officer and Principal Accounting Officer effective as of July 21, 2022. Prior to joining the Company, Mr. Subainati served as Controller at Crossbar, Inc., a semiconductor memory technology provider from July 2018 until January 2020. Mr. Subainati previously served as Corporate Controller of Sigma Designs, Inc. a Nasdaq-listed integrated system-on-chip solutions provider for home and industrial applications, from May 2014 until its acquisition by Silicon Labs, Inc. in June 2018. Earlier in his career Mr. Subainati worked at Ernst & Young and Deloitte. He received a B.S. in business administration with an accounting major from Santa Clara University. He earned and currently holds an active CPA designation.- Nabeel Subainati自2020年1月起担任公司副总裁兼公司财务总监。他被任命为Avinger, Inc.首席财务官和首席会计官，自2022年7月21日起生效。在加入本公司之前，Subainati先生于2018年7月至2020年1月担任半导体存储器技术提供商Crossbar，Inc.的财务总监。Subainati先生曾于2014年5月至2018年6月被Silicon Labs，Inc.收购之前担任西格玛设计公司的公司财务总监，该公司是一家在纳斯达克上市的家庭和工业应用集成片上系统解决方案提供商。在他职业生涯的早期，Subainati先生曾在Ernest & Young和Deloitte工作。他获得了学士学位在圣克拉拉大学获得工商管理学士学位，主修会计。他获得并目前持有有效的注册会计师称号。
- Nabeel Subainati,has served in multiple capacities since January 2020. Currently Mr. Subainati is serving as the Company's Vice President, Finance, formerly Mr. Subainati held the position of Vice President, Corporate Controller. He was appointed to serve as Avinger, Inc. Principal Financial Officer and Principal Accounting Officer effective as of July 21, 2022. Prior to joining the Company, Mr. Subainati served as Controller at Crossbar, Inc., a semiconductor memory technology provider from July 2018 until January 2020. Mr. Subainati previously served as Corporate Controller of Sigma Designs, Inc. a Nasdaq-listed integrated system-on-chip solutions provider for home and industrial applications, from May 2014 until its acquisition by Silicon Labs, Inc. in June 2018. Earlier in his career Mr. Subainati worked at Ernst & Young and Deloitte. He received a B.S. in business administration with an accounting major from Santa Clara University. He earned and currently holds an active CPA designation.
- Jeffrey M. Soinski
JeffreyM.Soinski自2014年12月以来一直担任我们的总裁，首席执行官和董事会成员。从2009年9月Unisyn成立到2013年5月GE梦百合收购Unisyn业务，索因斯基一直担任Medical Imaging Holdings及其主要运营公司Unisyn Medical Technologies的首席执行官，为医学影像行业提供技术支持的产品和服务的国家提供商。Soinski先生自2009年9月起担任Medical Imaging Holdings及其剩余运营公司Consensys Imaging Service的董事，直至2017年10月出售。Soinski先生于2008年7月至2013年6月定期担任特殊风险合伙人，并自2016年10月起担任Galen Partners的特殊投资合伙人，Galen Partners是一家专注于梦百合的领先私募股权公司，其中包括医疗影像控股公司作为其投资组合公司之一。Soinski从2001年到2008年被C.R.Bard收购，担任Specialized Health Products International（专有安全医疗产品上市制造商和营销商）总裁和首席执行官。他曾任职Merriman Holdings公司（Merriman Capital公司（位于旧金山的投资银行和经纪公司）的母公司）的董事会（从2008年到2016年3月）。Soinski先生持有Dartmouth College的学士学位。
Jeffrey M. Soinski,has served as Avinger, Inc. President, Chief Executive Officer and a member of Avinger, Inc. Board of Directors since December 2014. From its formation in September 2009 until the acquisition of its Unisyn business by GE Healthcare in May 2013, Mr. Soinski served as Chief Executive Officer of Medical Imaging Holdings and its primary operating company Unisyn Medical Technologies, a national provider of technology-enabled products and services to the medical imaging industry. Mr. Soinski was a Director of Medical Imaging Holdings and its remaining operating company Consensys Imaging Service from September 2009 until its sale in October 2017. Mr. Soinski served periodically as a Special Venture Partner from July 2008 to June 2013 and as a Special Investment Partner since October 2016 for Galen Partners, a leading healthcare-focused private equity firm, which included Medical Imaging Holdings as one of its portfolio companies. From 2001 until its acquisition by C.R. Bard in 2008, Mr. Soinski was President and CEO of Specialized Health Products International, a publicly-traded manufacturer and marketer of proprietary safety medical products. He served on the board of directors of Merriman Holdings, parent of Merriman Capital, a San Francisco-based investment banking and brokerage firm, from 2008 until March 2016. Mr. Soinski holds a B.A. degree from Dartmouth College.- JeffreyM.Soinski自2014年12月以来一直担任我们的总裁，首席执行官和董事会成员。从2009年9月Unisyn成立到2013年5月GE梦百合收购Unisyn业务，索因斯基一直担任Medical Imaging Holdings及其主要运营公司Unisyn Medical Technologies的首席执行官，为医学影像行业提供技术支持的产品和服务的国家提供商。Soinski先生自2009年9月起担任Medical Imaging Holdings及其剩余运营公司Consensys Imaging Service的董事，直至2017年10月出售。Soinski先生于2008年7月至2013年6月定期担任特殊风险合伙人，并自2016年10月起担任Galen Partners的特殊投资合伙人，Galen Partners是一家专注于梦百合的领先私募股权公司，其中包括医疗影像控股公司作为其投资组合公司之一。Soinski从2001年到2008年被C.R.Bard收购，担任Specialized Health Products International（专有安全医疗产品上市制造商和营销商）总裁和首席执行官。他曾任职Merriman Holdings公司（Merriman Capital公司（位于旧金山的投资银行和经纪公司）的母公司）的董事会（从2008年到2016年3月）。Soinski先生持有Dartmouth College的学士学位。
- Jeffrey M. Soinski,has served as Avinger, Inc. President, Chief Executive Officer and a member of Avinger, Inc. Board of Directors since December 2014. From its formation in September 2009 until the acquisition of its Unisyn business by GE Healthcare in May 2013, Mr. Soinski served as Chief Executive Officer of Medical Imaging Holdings and its primary operating company Unisyn Medical Technologies, a national provider of technology-enabled products and services to the medical imaging industry. Mr. Soinski was a Director of Medical Imaging Holdings and its remaining operating company Consensys Imaging Service from September 2009 until its sale in October 2017. Mr. Soinski served periodically as a Special Venture Partner from July 2008 to June 2013 and as a Special Investment Partner since October 2016 for Galen Partners, a leading healthcare-focused private equity firm, which included Medical Imaging Holdings as one of its portfolio companies. From 2001 until its acquisition by C.R. Bard in 2008, Mr. Soinski was President and CEO of Specialized Health Products International, a publicly-traded manufacturer and marketer of proprietary safety medical products. He served on the board of directors of Merriman Holdings, parent of Merriman Capital, a San Francisco-based investment banking and brokerage firm, from 2008 until March 2016. Mr. Soinski holds a B.A. degree from Dartmouth College.